Comment from Biocon Biologics
AnonymousSupportBusiness
Summary: Biocon Biologics Inc. supports the draft guidance but requests specific clarifications and revisions to reduce administrative burdens and protect legal privileges. They advocate for clearer definitions regarding response preparers, the use of consultants, and the development of a centralized submission portal for large files.
Kimberly Maxfield, PhD, MPH
Director of Regulatory Affairs – US
Biocon Biologics Inc.
685 Route 202/206, Suite 204
Bridgewater, NJ 08807
kimberlyelizabeth.maxfield@biocon.com
May 8, 2026
Food and Drug Administration
Dockets Management Staff (HFA-305)
5630 Fishers Lane, Room 1061
Rockville, MD 20852
Re: Docket No. FDA-2025-D-1504: Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection – Guidance for Industry
Dear Sir or Madam:
On behalf of Biocon Biologics Inc., I am pleased to submit comments to the above-referenced docket on the draft Guidance for Industry, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.
We appreciate the Agency’s efforts to provide clarity on preparing concise, factual, and effective responses to Form FDA 483 observations. As a global developer of biosimilars, we share FDA’s commitment to ensuring product quality and minimizing risks to patients and the public.
Our comments provide recommendations and requests for clarification intended to support FDA’s objectives and facilitate consistent, practical implementation by industry.
We appreciate the opportunity to provide input and would welcome further engagement with the Agency on these topics.
Respectfully submitted,
Kimberly Maxfield